SLC5A2 and type 2 diabetes mellitus: However, although this pilot study provides preliminary evidence supporting that empagliflozin might be useful for treatment of NASH, larger placebo-controlled RCTs are needed to assess the efficacy of SGLT-2 inhibitors for treatment of NASH in patients with or without T2DM.